Edition:
United States

MannKind Corp (MNKD.OQ)

MNKD.OQ on NASDAQ Stock Exchange Global Market

1.94USD
4:00pm EDT
Change (% chg)

$-0.04 (-2.02%)
Prev Close
$1.98
Open
$1.99
Day's High
$2.00
Day's Low
$1.90
Volume
314,104
Avg. Vol
465,310
52-wk High
$4.34
52-wk Low
$0.67

Chart for

About

MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic... (more)

Overall

Beta: 3.12
Market Cap(Mil.): $207.27
Shares Outstanding(Mil.): 104.68
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 78.94 16.33
EPS (TTM): -- -- --
ROI: -- 2.84 14.66
ROE: -- 4.61 13.99

BRIEF-Mannkind Corp resolved to voluntary delist from Tel Aviv Stock Exchange Ltd

* Mannkind corp - ‍on august 4, board resolved to voluntary delist its common stock from tel aviv stock exchange ltd - sec filing​

Aug 07 2017

BRIEF-MannKind Corporation reports 2017 second quarter financial results

* Q2 revenue $2.2 million Source text for Eikon: Further company coverage:

Aug 07 2017

BRIEF-MannKind and One Drop partner to launch the A-one clinical trial

* MannKind and One Drop partner to launch the A-one clinical trial

Aug 07 2017

BRIEF-Steven Binder joins MannKind as Chief Financial Officer

* MannKind Corp - ‍Steven Binder has joined company as its Chief Financial Officer​ Source text for Eikon: Further company coverage:

Jul 17 2017

BRIEF-Mannkind files for offer and sale of up to 7.3 mln shares of common stock issuable upon exercise of Series A common stock purchase warrants

* Mannkind Corp files for offer and sale of up to 7.3 million shares of common stock issuable upon exercise of Series A common stock purchase warrants

Jul 03 2017

BRIEF-Mannkind renegotiates near-term maturities with Deerfield

* Mannkind-Deerfield to amend terms of minimum liquidity covenant such that each month from October to December, company must maintain at least $10 million of cash & cash equivalents

Jun 29 2017

BRIEF-Mannkind draws remaining funds under Mann Group loan arrangement

* Mannkind- ‍delivered funding request notification to Mann Group pursuant to terms of Mann Group loan

Jun 29 2017

BRIEF-Mannkind engages Locust Walk to explore strategic options for non-insulin technosphere-based pipeline candidates

* Mannkind engages Locust Walk to explore strategic options for Mannkind’s non-insulin technosphere-based pipeline candidates

Jun 05 2017

BRIEF-Mannkind and Biomm enter into distribution agreement for Afrezza in Brazil​

* Mannkind and Biomm enter into distribution agreement for Afrezza in Brazil​ Source text for Eikon: Further company coverage:

May 31 2017

BRIEF-Mannkind board appoints Michael Castagna as CEO effective May 25, 2017

* Mannkind Corp - board of directors appointed Michael Castagna as chief executive officer effective may 25, 2017.

May 30 2017

Competitors

  Price Chg
Novo Nordisk A/S (NOVOb.CO) kr.306.40 +3.00
Pfizer Inc. (PFE.N) $35.97 -0.02
Sanofi SA (SASY.PA) €83.87 +1.57
Eli Lilly and Co (LLY.N) $83.33 +1.31
Nektar Therapeutics (NKTR.OQ) $21.87 +0.48
Albireo Pharma Inc (ALBO.OQ) $22.16 -0.32

Earnings vs. Estimates